Quick Answer
Celldex Therapeutics, Inc. reported Diluted EPS of $3.90 per share (loss) for fiscal year 2025.
Celldex Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.90 | -59.2% |
| 2024 | -$2.45 | +16.1% |
| 2023 | -$2.92 | -21.7% |
| 2022 | -$2.40 | -46.3% |
| 2021 | -$1.64 | +18.8% |
| 2020 | -$2.02 | +42.5% |
| 2019 | -$3.51 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.01 | -57.8% | -18.8% |
| June 30, 2025 | -$0.85 | -57.4% | -4.9% |
| March 31, 2025 | -$0.81 | -44.6% | -26.6% |
| September 30, 2024 | -$0.64 | +21.0% | -18.5% |
| June 30, 2024 | -$0.54 | +16.9% | +3.6% |
| March 31, 2024 | -$0.56 | +9.7% | +30.9% |
| September 30, 2023 | -$0.81 | -42.1% | -24.6% |
| June 30, 2023 | -$0.65 | +15.6% | -4.8% |
- Celldex Therapeutics, Inc. showed a decrease of -59.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Celldex Therapeutics, Inc.’s diluted eps has declined by 11.1% (from $3.51 per share (loss) to $3.90 per share (loss)).
- The most recent figure is from Celldex Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: